EX1N
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Exopharm Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm's principal activities include pipeline products analysis and selection; technology development and validation; and commercial collaborations. The firm operates through regenerative medicine and biopharmaceutical drug development segment. Its exosome technologies solve the needs for the success of exosome medicines. Its technologies include LEAP manufacturing technology, LOAD active pharmaceutical ingredients (APIs) loading technologies, and EVPS tropism technologies. The firm is developing Engineered EVs (EEVs), an emerging form of precision medicine with application in areas, such as neurology, cardiology, and oncology. Its EEV technology includes EVPS to provide tissue tropism to exosomes and LOAD to load in APIs, such as messenger ribonucleic acid (mRNA).
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in EX1N
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in EX1N
N/A
EX1N investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in EX1N also invest in...
ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.
🙌 Performance (5Yr p.a)
8.12%
📊 Share price
$36.81 AUD
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
🌏 GLOBAL
GRNV.AX was created on 2016-04-27 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. GRNV.AX gives investors access to a diversified portfolio of sustainable Australian companies selected on the basis of in-depth analysis by world leading research agency MSCI ESG Research. GRNV.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index.
🙌 Performance (5Yr p.a)
3.46%
📊 Share price
$32.49 AUD
🏭 INDUSTRIALS
💸 FINANCIALS
🇦🇺 AUSTRALIA
IMPQ.AX was created on 2021-09-29 by Perennial. The fund's investment portfolio concentrates primarily on total market equity. The objective of the Fund is to deliver long-term capital growth predominately through investments in Australian and New Zealand listed smaller and mid-cap companies that are Better Future Investments.
🙌 Performance (5Yr p.a)
1.12%
📊 Share price
$4.91 AUD
EX1DA
Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm invests in biopharmaceutical drug development. The firm is engaged in exosome technology and holds a portfolio of intellectual property and know-how related to exosomes and the manufacture of exosomes. The Company’s exosome technologies solve needs for the success of exosome medicines, LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies. The firm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome delivery for their own products.
🙌 Performance (5Yr p.a)
-18.71%
📊 Share price
$0.03 AUD
🧬 BIOTECHNOLOGY
Want more shares? Try these...
EX20.AX was created on 2016-10-05 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 392.85m in AUM and 181 holdings. EX20.AX aims to track the performance of an index (before fees and expenses) comprising the 180 largest stocks listed on the ASX, after excluding the 20 largest, based on their market capitalisation.
🙌 Performance (5Yr p.a)
3.33%
📊 Share price
$22.36 AUD
⛳️ DIVERSIFIED
EX1DA
Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm invests in biopharmaceutical drug development. The firm is engaged in exosome technology and holds a portfolio of intellectual property and know-how related to exosomes and the manufacture of exosomes. The Company’s exosome technologies solve needs for the success of exosome medicines, LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies. The firm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome delivery for their own products.
🙌 Performance (5Yr p.a)
-18.71%
📊 Share price
$0.03 AUD
🧬 BIOTECHNOLOGY